These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36751044)

  • 41. Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study.
    Kim J; Yoon H; Kim N; Lee KM; Jung SA; Choi CH; Kim ES; Jung Y; Eun CS; Kim TO; Kang SB; Kim YS; Seo GS; Lee CK; Im JP; Park SJ; Park DI; Ye BD
    Inflamm Bowel Dis; 2021 Nov; 27(12):1931-1941. PubMed ID: 33501935
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Aminosalicylates for induction of remission or response in Crohn's disease.
    Lim WC; Wang Y; MacDonald JK; Hanauer S
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD008870. PubMed ID: 27372735
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies.
    Narula N; Aruljothy A; Wong ECL; Homenauth R; Alshahrani AA; Marshall JK; Reinisch W
    United European Gastroenterol J; 2021 Jun; 9(5):581-589. PubMed ID: 34077627
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
    Feagan BG; Sandborn WJ; Gasink C; Jacobstein D; Lang Y; Friedman JR; Blank MA; Johanns J; Gao LL; Miao Y; Adedokun OJ; Sands BE; Hanauer SB; Vermeire S; Targan S; Ghosh S; de Villiers WJ; Colombel JF; Tulassay Z; Seidler U; Salzberg BA; Desreumaux P; Lee SD; Loftus EV; Dieleman LA; Katz S; Rutgeerts P;
    N Engl J Med; 2016 Nov; 375(20):1946-1960. PubMed ID: 27959607
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adalimumab for induction of remission in Crohn's disease.
    Abbass M; Cepek J; Parker CE; Nguyen TM; MacDonald JK; Feagan BG; Khanna R; Jairath V
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31742665
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn's Disease.
    Painchart C; Brabant S; Duveau N; Nachury M; Desreumaux P; Branche J; Gérard R; Prevost CLD; Wils P; Lambin T; Boualit M; Labalette M; Pariente B
    Dig Dis Sci; 2020 May; 65(5):1445-1452. PubMed ID: 31599389
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn's disease: A systematic review and meta-analysis.
    Yoshihara T; Shinzaki S; Amano T; Iijima H; Takehara T; Inoue N; Uchino M; Esaki M; Kobayashi T; Saruta M; Sugimoto K; Nakamura S; Hata K; Hirai F; Hiraoka S; Fujii T; Matsuura M; Matsuoka K; Watanabe K; Nakase H; Watanabe M
    J Gastroenterol Hepatol; 2021 Jul; 36(7):1744-1753. PubMed ID: 33450096
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Certolizumab pegol for induction of remission in Crohn's disease.
    Yamazaki H; So R; Matsuoka K; Kobayashi T; Shinzaki S; Matsuura M; Okabayashi S; Kataoka Y; Tsujimoto Y; Furukawa TA; Watanabe N
    Cochrane Database Syst Rev; 2019 Aug; 8(8):CD012893. PubMed ID: 31476018
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of ustekinumab trough levels during induction and maintenance therapy with regard to disease activity status in difficult to treat Crohn disease patients.
    Mechie NC; Burmester M; Mavropoulou E; Pilavakis Y; Kunsch S; Ellenrieder V; Amanzada A
    Medicine (Baltimore); 2021 Mar; 100(11):e25111. PubMed ID: 33725990
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy.
    Forbes GM; Sturm MJ; Leong RW; Sparrow MP; Segarajasingam D; Cummins AG; Phillips M; Herrmann RP
    Clin Gastroenterol Hepatol; 2014 Jan; 12(1):64-71. PubMed ID: 23872668
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ustekinumab is associated with superior treatment persistence but not with higher remission rates
    Bacsur P; Matuz M; Resál T; Miheller P; Szamosi T; Schäfer E; Sarlós P; Iliás Á; Szántó K; Rutka M; Bálint A; Milassin Á; Fábián A; Bor R; Szepes Z; Molnár T; Farkas K
    Therap Adv Gastroenterol; 2022; 15():17562848221144349. PubMed ID: 36600684
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antibiotics for induction and maintenance of remission in Crohn's disease.
    Townsend CM; Parker CE; MacDonald JK; Nguyen TM; Jairath V; Feagan BG; Khanna R
    Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012730. PubMed ID: 30731030
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidence.
    Engel T; Yung DE; Ma C; Pariente B; WIls P; Eliakim R; Ungar B; Ben-Horin S; Kopylov U
    Dig Liver Dis; 2019 Sep; 51(9):1232-1240. PubMed ID: 31202609
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association between Ustekinumab Trough Levels, Serum IL-22, and Oncostatin M Levels and Clinical and Biochemical Outcomes in Patients with Crohn's Disease.
    Bertin L; Barberio B; Gubbiotti A; Bertani L; Costa F; Ceccarelli L; Visaggi P; Bodini G; Pasta A; Sablich R; Urbano MT; Ferronato A; Buda A; De Bona M; Del Corso G; Massano A; Angriman I; Scarpa M; Zingone F; Savarino EV
    J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38541765
    [No Abstract]   [Full Text] [Related]  

  • 55. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
    Ferrante M; Panaccione R; Baert F; Bossuyt P; Colombel JF; Danese S; Dubinsky M; Feagan BG; Hisamatsu T; Lim A; Lindsay JO; Loftus EV; Panés J; Peyrin-Biroulet L; Ran Z; Rubin DT; Sandborn WJ; Schreiber S; Neimark E; Song A; Kligys K; Pang Y; Pivorunas V; Berg S; Duan WR; Huang B; Kalabic J; Liao X; Robinson A; Wallace K; D'Haens G
    Lancet; 2022 May; 399(10340):2031-2046. PubMed ID: 35644155
    [TBL] [Abstract][Full Text] [Related]  

  • 56. USTEKINUMAB IN CROHN'S DISEASE MANAGEMENT: A BRAZILIAN OBSERVATIONAL STUDY.
    Castro PCS; Magro DO; Nones RB; Furlan TK; Miranda EF; Kotze PG
    Arq Gastroenterol; 2022; 59(4):501-507. PubMed ID: 36515346
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Natalizumab for induction of remission in Crohn's disease.
    Nelson SM; Nguyen TM; McDonald JW; MacDonald JK
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006097. PubMed ID: 30068022
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
    Colombel JF; Panaccione R; Bossuyt P; Lukas M; Baert F; Vaňásek T; Danalioglu A; Novacek G; Armuzzi A; Hébuterne X; Travis S; Danese S; Reinisch W; Sandborn WJ; Rutgeerts P; Hommes D; Schreiber S; Neimark E; Huang B; Zhou Q; Mendez P; Petersson J; Wallace K; Robinson AM; Thakkar RB; D'Haens G
    Lancet; 2017 Dec; 390(10114):2779-2789. PubMed ID: 29096949
    [TBL] [Abstract][Full Text] [Related]  

  • 59. P066 Real-World Experience of Ustekinumab in Crohn's Disease Patients With Prior Anti-TNF Therapy at a Tertiary Care Hospital.
    Tripathi K; Groudan K; Chalhoub J; Yedla A; Singhania R
    Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S17. PubMed ID: 37461983
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study.
    Chaparro M; Baston-Rey I; Fernández-Salgado E; González García J; Ramos L; Diz-Lois Palomares MT; Argüelles-Arias F; Iglesias Flores E; Cabello M; Rubio Iturria S; Núñez Ortiz A; Charro M; Ginard D; Dueñas Sadornil C; Merino Ochoa O; Busquets D; Iyo E; Gutiérrez Casbas A; Ramírez de la Piscina P; Boscá-Watts MM; Arroyo M; García MJ; Hinojosa E; Gordillo J; Martínez Montiel P; Velayos Jiménez B; Quílez Ivorra C; Vázquez Morón JM; María Huguet J; González-Lama Y; Muñagorri Santos AI; Amo VM; Martín-Arranz MD; Bermejo F; Martínez Cadilla J; Rubín de Célix C; Fradejas Salazar P; San Román AL; Jiménez N; García López S; Figuerola A; Jiménez I; Martínez Cerezo FJ; Taxonera C; Varela P; de Francisco R; Monfort D; Molina Arriero G; Hernández Camba A; García-Alonso FJ; Van Domselaar M; Pajares Villarroya R; Núñez A; Rodríguez Moranta F; Marín-Jiménez I; Robles Alonso V; Martín Rodríguez MDM; Camo-Monterde P; García Tercero I; Navarro Llavat M; Arias García L; Hervías Cruz D; Sulleiro S; Novella C; Vispo E; Barreiro-de Acosta M; Gisbert JP
    Inflamm Bowel Dis; 2022 Nov; 28(11):1725-1736. PubMed ID: 35166347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.